DETERMINATION OF ADVERSE EVENTS RATE AND SOME RELATED FACTORS IN OUT PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS AT VINH LONG

Nhật Quang Nguyễn1,, Thị Linh Tuyền Nguyễn1
1 Can Tho University of Medicine - Pharmacy

Main Article Content

Abstract

Objective: to determine the incidence of adverse events and some related factors in patiens with multi-resistant tuberculosis at Vinh Long Lung hospital from 2020 to 2022. Materials and methods: a descriptive study of a cluster of cases based on 131 outpatient records who started treatment for multidrug-resistant tuberculosis (MDR-TB) at Vinh Long Lung hospital, form January 2020 to December 2022. Data were collected and analyzed by using Excel 16 and SPSS 20.0 software, using Chi-square test with 95% confidence level. Results: out of a total of 131 outpatient medical records and 465 adverse events, the number of medical records with at least one adverse event was 115, accounting for 87,8%. In which, joint pain was the most common event with 51,9%, dizziness 50,4%, nausea or vomiting 49,6%, increased liver enzymes 46,6%, itching 42% besides some lessfrequent events were headache 3,8%, visual changes 7,6%, tinnitus or deafness 7,6%, prolongation of QT interval 7,6%. Several factors associated with the occurrence of adverse events were identified in the event of arthralgia and elevation of liver enzymes. For joint pain events, the relevant factors are the duration of treatment and drug content. In the event of elevation of liver enzymes, drug content, age and duration of treatment are related factors. Conclusion: the incidence of adverse events during the treatment of MDR-TB is still quite high, it is necessary to pay attention to related factors such as the use of drug content and duration of treatment for monitoring and limiting adverse events in out patients treated with MDR-TB.

Article Details

References

1. Nguyễn Thị Vân Anh, Nguyễn Hoàng Anh & Trần Ngân Hà (2021), "Tổng kết công tác báo cáo ADR năm 2020", Trung tâm DI & ADR Quốc gia.
2. Nguyễn Hải Bình (2019), "Phân tích biến cố bất lợi liên quan đến thuốc lao hàng một tại bệnh viện lao và phổi Quảng Ninh", luận văn dược sĩ chuyên khoa cấp 1, Trường Đại học dược Hà Nội.
3. Bộ Y Tế (2021), Tài liệu tập huấn hướng dẫn chẩn đoán, điều trị và dự phòng bệnh lao, quyết định 1314/QĐ-BYT ngày 23/04/2021 của Bộ Y Tế.
4. Cao Thị Thu Huyền (2017), "Phân tích biến cố bất lợi trên bệnh nhân sử dụng phác đồ điều trị lao đa kháng tại một số cơ sở trọng điểm", Luận văn thạc sĩ Dược,Đại học Dược Hà Nội.
5. Ahmad, N., Javaid, A., Syed Sulaiman, et al. (2018), "Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients", Am J Ther, 25(5), pp.e533-e540.
6. Chakaya, J., Khan, M., Ntoumi, et al. (2021), "Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts", Int J Infect Dis, 113 Suppl 1, pp.S7-S12.
7. Fatima, Maria Fatima Syeda, Nagesh Adla and Rama Devi (2021), “Ambispec-tive study of adverse drug reactions in multi-drug resistant tuberculosis patients in Warangal, Telangana”.
8. Fukunaga, R., Glaziou, et al. (2021), "Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2019", MMWR Morb Mortal Wkly Rep, 70(12), pp.427-430.